Cytosorbents Corp (CTSO) Given a $12.00 Price Target by HC Wainwright Analysts
Cytosorbents Corp (OTCMKTS:CTSO) has been assigned a $12.00 price objective by research analysts at HC Wainwright in a research note issued to investors on Tuesday. The brokerage presently has a a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 101.68% from the company’s previous close.
Other equities research analysts also recently issued reports about the stock. B. Riley assumed coverage on shares of Cytosorbents Corp in a research note on Thursday. They issued a “buy” rating and a $11.25 price target for the company. Maxim Group reissued a “buy” rating and set a $8.00 target price on shares of Cytosorbents Corp in a research report on Wednesday, October 5th. Finally, Brean Capital assumed coverage on shares of Cytosorbents Corp in a research report on Tuesday, October 4th. They set a “buy” rating and a $24.00 target price for the company. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $13.65.
Shares of Cytosorbents Corp (OTCMKTS:CTSO) traded up 1.261% during midday trading on Tuesday, reaching $6.025. 202,558 shares of the company’s stock traded hands. Cytosorbents Corp has a 12 month low of $3.11 and a 12 month high of $8.10. The stock has a 50-day moving average price of $5.74 and a 200 day moving average price of $4.81. The firm’s market cap is $153.26 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/cytosorbents-corp-ctso-given-a-12-00-price-target-by-hc-wainwright-analysts.html
Cytosorbents Corp (OTCMKTS:CTSO) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.03. The business had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $2.18 million. Equities research analysts predict that Cytosorbents Corp will post ($0.39) earnings per share for the current year.
A number of large investors have recently modified their holdings of the company. Advisor Group Inc. bought a new position in Cytosorbents Corp during the second quarter worth $1,372,000. Raymond James & Associates boosted its position in Cytosorbents Corp by 318.6% in the second quarter. Raymond James & Associates now owns 324,603 shares of the company’s stock worth $1,477,000 after buying an additional 247,052 shares during the last quarter. BlackRock Fund Advisors boosted its position in Cytosorbents Corp by 39.3% in the second quarter. BlackRock Fund Advisors now owns 53,915 shares of the company’s stock worth $245,000 after buying an additional 15,203 shares during the last quarter. Vanguard Group Inc. boosted its position in Cytosorbents Corp by 1.0% in the second quarter. Vanguard Group Inc. now owns 537,707 shares of the company’s stock worth $2,447,000 after buying an additional 5,446 shares during the last quarter. Finally, Douglass Winthrop Advisors LLC bought a new position in Cytosorbents Corp during the second quarter worth $321,000.
Cytosorbents Corp Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.